H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best oversold NASDAQ stocks to buy now. On June 30, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) and set a price target of $102.00.

On June 25, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, which is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Management reported that VK2375 is under development in both subcutaneous and oral formulations to potentially treat metabolic disorders such as obesity.

The VANQUISH Phase 3 program encompasses two studies evaluating VK2735: one in obese or overweight adults with type 2 diabetes and one in adults with obesity.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage company that develops therapies for metabolic and endocrine disorders.

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.